Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin to Increase Endometrial Mesenchymal Stem Cells in Recurrent Miscarriage
2016-001120-54Phase 2Completed
- Sponsor
- University Hospitals Coventry and Warwickshire NHS Trust
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sitagliptin in recurrent miscarriage (RPL) (2 arms), sponsored by University Hospitals Coventry and Warwickshire NHS Trust. Primary endpoint: Endometrial mesenchymal stem cell colonies. Started Jul 2016; status: completed.
02
Drugs
sitagliptin
03
Conditions
recurrent miscarriage (RPL)
Beyond the preview
Go deeper on 2016-001120-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001120-54.